Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

Trial Profile

A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary) ; Low molecular weight heparins (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Hokusai-VTE Cancer
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 13 Dec 2022 Results of post hoc analysis investigating the impact of platelet count on bleeding and recurrent thrombosis, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 29 Aug 2021 Results of nested case-control study assessing risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban and identify patients with gastrointestinal cancer at low risk of bleeding in whom edoxaban can be safely prescribed, published in the Journal of Thrombosis and Haemostasis.
    • 04 Jul 2019 Post hoc analysis results (n=1046) were published in the Journal of Thrombosis and Haemostasis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top